Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05764954 | A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | PHASE1 | RECRUITING | 25 | — | — | Aug 4, 2023 | Aug 1, 2027 | Apr 9, 2026 | 7 | United States |
based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
| Arm | Type | Description |
|---|---|---|
| NovoTTF-200T System Tumor-Treating Fields (TTFields) | EXPERIMENTAL | Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week). |
| Name | Type | Description |
|---|---|---|
| NovoTTF-200T System | DEVICE | The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week). |
Inclusion Criteria: * The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study. * The participant is ≥22 years of age on the day of signing informed consent. * The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung A...